381 related articles for article (PubMed ID: 33015092)
21. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
Bahap-Kara M; Duran E; Bayraktar-Ekincioglu A; Karadag O
Intern Emerg Med; 2023 Apr; 18(3):791-799. PubMed ID: 36826744
[TBL] [Abstract][Full Text] [Related]
22. Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center.
Berardicurti O; Pavlych V; Cola ID; Ruscitti P; Di Benedetto P; Navarini L; Marino A; Cipriani P; Giacomelli R
J Rheumatol; 2022 Feb; 49(2):171-175. PubMed ID: 34654730
[TBL] [Abstract][Full Text] [Related]
23. Do the European League Against Rheumatism (EULAR) Sjögren's syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren's syndrome?
Omma A; Tecer D; Kucuksahin O; Sandikci SC; Yildiz F; Erten S
Arch Med Sci; 2018 Jun; 14(4):830-837. PubMed ID: 30002701
[TBL] [Abstract][Full Text] [Related]
24. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
25. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
26. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
[TBL] [Abstract][Full Text] [Related]
27. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients.
Cho HJ; Yoo JJ; Yun CY; Kang EH; Lee HJ; Hyon JY; Song YW; Lee YJ
Rheumatology (Oxford); 2013 Dec; 52(12):2208-17. PubMed ID: 24023247
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Pu J; Wang X; Riaz F; Zhang T; Gao R; Pan S; Wu Z; Liang Y; Zhuang S; Tang J
Front Pharmacol; 2021; 12():621208. PubMed ID: 33815105
[No Abstract] [Full Text] [Related]
30. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
[TBL] [Abstract][Full Text] [Related]
31. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
33. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
[TBL] [Abstract][Full Text] [Related]
34. B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome.
James K; Chipeta C; Parker A; Harding S; Cockell SJ; Gillespie CS; Hallinan J; Barone F; Bowman SJ; Ng WF; Fisher BA;
Rheumatology (Oxford); 2018 Jul; 57(7):1222-1227. PubMed ID: 29608774
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
36. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
37. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
39. Fatigue in Saudi Patients with Primary Sjögren's Syndrome and Its Correlation with Disease Characteristics and Outcome Measures: A Cross-Sectional Study.
AlEnzi F; Alqahtani B; Alhamad EH; Daghestani M; Tashkandy Y; Othman N; Alshahrani K; Paramasivam MP; Halwani R; Omair MA
Open Access Rheumatol; 2020; 12():303-308. PubMed ID: 33293878
[TBL] [Abstract][Full Text] [Related]
40. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
